VYNE vs. MURA

Last updated Apr 2, 2026

Compare and contrast key facts about VYNE Therapeutics Inc. (VYNE) and Mural Oncology plc (MURA).

Performance

VYNE vs. MURA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in VYNE Therapeutics Inc. (VYNE) and Mural Oncology plc (MURA). The values are adjusted to include any dividend payments, if applicable.

VYNE vs. MURA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
VYNE VYNE Therapeutics Inc.	4.46%	-82.68%	43.78%	-41.46%
MURA Mural Oncology plc	0.00%	-36.65%	-45.61%	55.79%

Fundamentals

Market Cap VYNE : $25.92M MURA : $35.34M
EPS VYNE : -$0.62 MURA : -$6.89
PB Ratio VYNE : 0.93 MURA : 0.64
Total Revenue (TTM) VYNE : $570.00K MURA : $0.00
Gross Profit (TTM) VYNE : $0.00 MURA : -$1.10M
EBITDA (TTM) VYNE : -$28.33M MURA : -$118.31M

Returns By Period

VYNE

• 1D: 1.42%
• 1M: 0.17%
• YTD: 4.46%
• 6M: 78.76%
• 1Y: -60.39%
• 3Y*: -41.84%
• 5Y*: -65.53%
• 10Y*: —

MURA

• 1D: 0.00%
• 1M: 0.00%
• YTD: 0.00%
• 6M: -1.45%
• 1Y: 64.52%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VYNE vs. MURA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VYNE

VYNE Risk / Return Rank: 24
VYNE Sharpe Ratio Rank: 19
VYNE Sortino Ratio Rank: 31
VYNE Omega Ratio Rank: 31
VYNE Calmar Ratio Rank: 15
VYNE Martin Ratio Rank: 24

MURA

MURA Risk / Return Rank: 59
MURA Sharpe Ratio Rank: 59
MURA Sortino Ratio Rank: 96
MURA Omega Ratio Rank: 98
MURA Calmar Ratio Rank: 19
MURA Martin Ratio Rank: 22

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VYNE vs. MURA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for VYNE Therapeutics Inc. (VYNE) and Mural Oncology plc (MURA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VYNE	MURA	Difference
Sharpe ratio Return per unit of total volatility	-0.50	0.54	-1.04
Sortino ratio Return per unit of downside risk	0.08	3.77	-3.69
Omega ratio Gain probability vs. loss probability	1.01	1.70	-0.68
Calmar ratio Return relative to maximum drawdown	-0.73	-0.62	-0.11
Martin ratio Return relative to average drawdown	-0.94	-1.00	+0.06
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VYNE vs. MURA - Sharpe Ratio Comparison

The current VYNE Sharpe Ratio is -0.50, which is lower than the MURA Sharpe Ratio of 0.54. The chart below compares the historical Sharpe Ratios of VYNE and MURA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VYNE	MURA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.50	0.54	-1.04
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.62	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.60	-0.21	-0.39

Correlation

The correlation between VYNE and MURA is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VYNE vs. MURA - Dividend Comparison

Neither VYNE nor MURA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

VYNE vs. MURA - Drawdown Comparison

The maximum VYNE drawdown since its inception was -99.99%, which is greater than MURA's maximum drawdown of -83.44%. Use the drawdown chart below to compare losses from any high point for VYNE and MURA.

Drawdown Indicators

	VYNE	MURA	Difference
Max Drawdown Largest peak-to-trough decline	-99.99%	-83.44%	-16.55%
Max Drawdown (1Y) Largest decline over 1 year	-84.73%	-47.99%	-36.74%
Max Drawdown (5Y) Largest decline over 5 years	-99.77%	—	—
Current Drawdown Current decline from peak	-99.98%	-66.06%	-33.92%
Average Drawdown Average peak-to-trough decline	-92.94%	-46.24%	-46.70%
Ulcer Index Depth and duration of drawdowns from previous peaks	65.48%	48.33%	+17.15%

Volatility

VYNE vs. MURA - Volatility Comparison

VYNE Therapeutics Inc. (VYNE) has a higher volatility of 11.63% compared to Mural Oncology plc (MURA) at 0.00%. This indicates that VYNE's price experiences larger fluctuations and is considered to be riskier than MURA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VYNE	MURA	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.63%	0.00%	+11.63%
Volatility (6M) Calculated over the trailing 6-month period	55.87%	31.67%	+24.20%
Volatility (1Y) Calculated over the trailing 1-year period	121.79%	155.07%	-33.28%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	106.06%	116.96%	-10.90%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	104.36%	116.96%	-12.60%

Financials